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The Roles of the Subunits in the Function of the
Calcium Channel
DAFNA SINGER, MARTIN BIEL, ILANA LOTAN, VErr FLOCKERZI,
FRANz HOFMANN, NATHAN DASCAL*
Dihydropyridine-sensitive voltage-dependent L-type calcium channels are critical to
excitation-secretion and excitation-contraction coupling. The channel molecule is a
complex of the main, pore-forming subunit al and four additional subunits: a2, 8, A,
and y (a2 and 8 are encoded by a single messenger RNA). The a, subunit messenger
RNA alone directs expression of functional calcium channels in Xenopus oocytes, and
coexpression ofthe a2/8 and 1, subunits enhances the amplitude ofthe current. The a2,
8, and -y subunits also have pronounced effects on its macroscopic characteristics, such
as kinetics, voltage dependence of activation and inactivation, and enhancement by a
dihydropyridine agonist. In some cases, specific modulatory functions can be assigned
to individual subunits, whereas in other cases the different subunits appear to act in
concert to modulate the properties of the channel.
T HE DIHYDROPYRIDINE (DHP)-SEN-
sitive Ca2' channel protein of the
skeletal muscle (SM) consists of five
subunits, al1, a2, 8, 13, and y (1). The a,
subunit contains the binding site for DHPs
and other classical organic Ca21 channel
blockers (2), is the pore-forming subunit
(1-4), and is indispensable for the function
of the channel (5-8). A single a2/b mRNA
encodes the precursor protein aj8, which is
proteolysed into the 8 and a2 subunits,
linked by disulfide bonds (1, 9). The cDNAs
of the aj8, 1, and y subunits have been
cloned from SM (10-13). Identical or ho-
mologous proteins are found in brain (a2b8,
13), smooth muscle (aJ8, y), and heart
(a2I8, 1) (6, 10-15). Functional Ca21 chan-
nels can be expressed in Xenopus oocytes
injected with RNA of the a, subunits from
heart, smooth muscle, and brain (6-8); co-
expression of SM aJb and 1 with cardiac
and braina, subunit enhances the expressed
Ca21 currents, whereas the y subunit is
without effect (6, 8). The electrophysiolog-
D.Singer, I. Lotan, N. Dascal, Department of Physiol-
ogy and Pharmacology, Sackler School of Medicine, Tel
Aviv University, Ramat Aviv 69978, Israel.
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ical properties of the channel have been
reported to be unaffected by the auxiliary
subunits (6, 8). We have investigated this
problem by coexpressing the Ca2' channel
subunits in various combinations in Xenopus
oocytes and examining the macroscopic
characteristics of the current through the
emerging Ca2' channels.
cRNAs of cardiac al subunit and of SM
a,8], 13 and y subunits were synthesized in
vitro and injected into Xenopus oocytes (16).
After cRNA injection (4 to 5 days), we
measured currents using the two-electrode
voltage-clamp method, usually in a solution
containing 40 mM BaCl2 (16), because
Ba2` results in a larger current through the
Ca2' channel.
Uninjected oocytes displayed a small en-
dogenous Ba21 current, IBa (Table 1), that
was insensitive to the DHP agonist (-) Bay
K 8644 (Bay K) (17). A small, Bay K-sen-
sitive IBa was observed in oocytes injected
with the cRNA of theal subunit alone (0 to
-50 nA) (Fig. 1). Coexpression in the a2s8
or 13 subunit with a, consistently enhanced
the expressed currents, and coexpression of
both a2Jb and 1 with a, caused more than
additive increase in the amplitude of IBa
(Table 1). The y subunit did not have a
consistent effect on the amplitude of IBa
(Table 1). Since the auxiliary subunits sim-
ilarly enhance the expression of a brainCa21
channel (6), this phenomenon may be com-
mon to a variety of Ca21 channels.
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Injection of cRNA combinations that
did not contain the cardiac a1 cRNA (Ta-
ble 1 and Fig. 1), yielded small, Bay K-in-
sensitive currents that were larger than, but
otherwise similar to, the IBa of the native
oocyte and were similarly (17, 18) blocked
by Ni2' (not shown). These currents prob-
ably resulted from the association of the
newly synthesized a2Jb and 1 subunits with
a native DHP-insensitive a1 subunit exist-
ing in the oocyte. The y subunit was
apparently unable to associate with endog-
enous a1, and even caused a decrease in the
current amplitude (compare groups aJb +
1 and aL + 13 + y) (Table 1), possibly
because of the competition of RNAs for
polysomes (19).
The IBa (at 0 mV) was potentiated by Bay
K (0.5 jiM) in all groups containing the aL
subunit (Fig. 1), but with different efficien-
cy; a1 + aJ2/ + 13 was the least sensitive
combination (Table 1). This effect could
result from a direct influence ofthe auxiliary
subunits on drug binding or from different
voltage dependence of IBa in the different
groups (see below). A DHP blocker, (+)
PN 200-110 (1 pgM), and a phenylalkyl-
amine blocker, verapamil (20 gIM), effec-
tively blocked IBa in groups containing the
cardiac a1.
To investigate the macroscopic activation
of IBa, we measured the time by which IBa
reaches 90% of its peak amplitude (90%
up). The 90% up at 0 mV was independent
OfIBa amplitude within each group and was
uniform in all groups containing a2/b (-20
ms), but was slower in groups without a2/b
(34 to 56 msec) (Fig. 2A and Table 1).
Combinations that presumably associated
with the native a1 (ajb + 1 and aJb +
P3+y) had the fastest activation (-10 msec)
(Table 1). Activation OfIBa directed by the
cardiac a1 subunit alone is a few tens of
milliseconds, which is slower than in car-
diac cells but several times faster than in
skeletal muscle (>150 msec) (20). Thus,
the activation kinetics of Ca21 channels is
determined both by nature of the a1 sub-
unit and by subunit composition, especial-
ly by a2/8.
We also investigated the kinetics of mac-
roscopic inactivation of IBa. The decay rate
was quantified as the decrease in IBa from
the peak to the value 770 msec after the
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Fig. 1. Examples of IBa obtained by steps from
-100 to 0 mV in oocytes injected with cRNAs of
various subunits, and the effect of 0.5 AM (-)
Bay K 8644. Net IBa was obtained by the Cd'2-
subtraction procedure (by subtraction of currents
recorded in the presence of 0.2 to 0.4 MM Cd2+)
in 40 mM BaCI2 in all figures.
beginning of depolarization, expressed as
percent ofpeak amplitude (dec770) (21). The
decay of IBa became faster when the current
exceeded 1.5 to 2 pLA, suggesting the inter-
ference of a current-dependent inactivation
process (22) or a Ba2+-activated outward
current, probably carried by C1-, since it
was not observed when methanesulfonate
replaced Cl- in the external solution (23).
However, in all groups, for IBa < 850 nA,
the decay ofIBa did not depend on the entry
of Ba2`, because (i) dec770 was independent
of current amplitude, and (ii) the inactiva-
tion kinetics were not appreciably altered by
replacing external Cl- with methanesulfo-
nate (not shown). Therefore, we only ana-
lyzed inactivation kinetics of currents <850
nA.
The inactivation kinetics depended on
subunit composition (Fig. 2B). At 0 mV,
the current directed by the a1 subunit alone
showed little time-dependent inactivation;
addition of either 1 or a2Jb to al did not
significantly accelerate the decay. However,
the decay was much faster in groups con-
taining the y subunit or both aJ2/ and p
(Fig. 2B and Table 1). In most groups, the
decay of IBa became faster with stronger
Fig. 2. Activation and inac- A 0 - B
tivation kinetics of IBa at 0 0
mV. (A) Comparison of the -200 0 2/6+#
rising phase of IBa in two I
-
I
oocytes from groupsa1 + y 50a + /++0
and a,+ a2,]+ y. (B) ~0
Decay of IBa of comparable a\ +Y U-100 -
amplitudes in oocytes of dif- 600 - of1+/
ferent groups. Relatively + / -150 -_ 2
small currents are shown to -800 1 2
allow composition with the ' ' ' '
aJ2/8 + 0combinationwith- -20 0 20 40 60 0.0 0.4 0.8
out scaling. In all groups, Time msec) Tin*(a)
the kinetics of the decay was unchanged in the range 60 to 800 nA. The "addition" of y produced the
strongest acceleration (compare a1 and a1 + y, P < 0.01; a1 + a2J/ and a1 + aJ2T + y, P < 0.01;
a1 + 13 and a1 + 13 + -y, P < 0.02; a1 + aJ8 + 13 and a1 + aL28 + 1 + -y, P < 0.05). The addition
of a2b or 13 accelerated the decay in one case each (al + a2/8 or a1 + P versus aL + a218 + 1, P <
0.001) but not in other cases (a1 versus aL + 1, P > 0.2; a1 versus a, + a]&8, P > 0.05; a, + y versus
al + 1 + -y, P > 0.5; a1 + a%/ + y versus a1 + a21& + 13 + -y, P > 0.1; a1 + _y versus a1 + aJ/
+ y, P > 0.5). P was calculated with a two-tailed t test with a Bonferroni-like correction.
A
a b C -42, -28
m..JJ -14
56
42
125 msc 14
Fig. 3. Voltage-dependence
ofIBa activation. (A) An ae-
ample of the Cd2+-subtrac-
tion procedure used to ob-
tain net IBa: a, total currents
evoked by depolarizing
pulses to diffirent voltages;
b, the same as a in the pres-
ence of 0.4 mM CdCI2; c,
net IBa after digital subtrac-
tion of traces in b from
those in a, with voltages (in
millivolts) shown near each
trace; d, the -Vcurve in the
same cell as a through c. (B)
I-V curves in representative
oocytes of four other
groups. Ihe currents were
normalized to the peak.
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depolarization, and this phenomenon did
not depend on current amplitude (Fig. 3A,
C), suggesting a voltage-dependent inactiva-
tion process (22).
The voltage dependence of the channel
activation was determined mainly by al,
since the current-voltage (I-V) curves of
currents through channels directed by the a1
subunit alone (6, 7) are similar to those
directed by most other subunit combina-
tions (Fig. 3). The peak of the I-V curve in
most groups was between 15 and 30 mV.
However, in the al1 + aL2 + P3 group IBa
activated and peaked at more negative
potentials (Fig. 3 and Table 1), again imply-
ing a modulation by, and a synergy between
the aJb and P subunits. Addition of y to
most subunit combinations slightly shifted
the peak of the I-V curve to more positive
voltages (Table 1).
1.0
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0.0
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We then measured steady-state inactiva-
tion of IBa with 5-s inactivating prepulses
(Fig. 4 and Table 2). The steady-state inac-
tivation curves were fitted to a Boltzmann
equation (24). The inactivation of a1 sub-
unit-directed currents showed low voltage
sensitivity [half-inactivation voltage (V1/2),
-7 mV)] (25). Addition of a2Jb or y, but
not 1, shifted the V1/2 to negative voltages;
addition of a2J and 1 jointly also reduced
the slope factor Ki (that is, increased the
slope of the inactivation curve). The largest
effect was a strong negative shift in V112,
caused in any subunit combination by the
"addition" of the y subunit (Fig. 4). The
presence of -y set V112 and K1 in relatively
narrow ranges (-30 to -45 mV and 13 to
20 mV, respectively). The inactivation pa-
rameters were independent of the presence
of y in groups that did not contain the
1.0
0.5
0.0
0
B
m
400 ml 2/
-30t
-
400p
-120 -80 -40
Vp~p**g. (mY)
1.0
0.5
nr n
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1
* * I I.JU I . . W I . . . I .
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Fig. 4. Voltage dependence of inacti- E 1.0
vation of IBa. (A through D) Examples
of inactivation curves and net IBa (in-
sets) in representative oocytes from
various groups. The currents were ex-
amined with a two-pulse protocol: a 0.o5-s prepulse to different voltages (start- Z 0.5 fg e
ing from -100 mV, with a 10-mV b
increment), followed by a test pulse to d
20 mV. The curves were drawn with
the Bolzmann equation (24) with the
following parameters in (A through 0.0
D), respectively: V112, 0.8, -14.4, -120 -80 -40 0 40
-5.8, -43 mV; Ki, 15.5, 15.6, 7.6, -2 8
-0 0 4015.3 mV. (E) Average inactivation P (my)
curves drawn with the Bolzmann equa-
tion and the parameters from Table 2. The letters near the traces correspond to the subunit
combinations: a, a, in the presence of Bay K (25); b, al + 13; c, al + a2/8; d, a1 + aJb + 13; e, al
+ + y; f, a1 + atjb + + y; g, a2/b + 1; h, ao + aJ2/ + y.
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cardiac a1, suggesting the y does not asso-
ciate with the endogenous al or does not
affect its properties.
In 2 mM Ba2+, V112 was shifted to more
negative voltages compared to 40 mM Ba21
(Table 2), and this change was larger in the
presence of the y subunit than in its absence
(Table 2), suggesting that the y subunit
causes addition of negative charges in the
vicinity of the external mouth ofthe channel
(26). Thus, some of its external, negatively
charged groups may be close to the voltage-
sensing parts of al, and this implies an
intimate contact and a strong interaction
between y and al subunits.
In this report we demonstrate that the
auxiliary subunits of the SM Ca21 channel
have pronounced effects on the biophysical
and pharmacological properties of the cardi-
ac Ca21 channel: kinetics of activation and
inactivation, voltage dependence, and en-
hancement by Bay K. Our data suggest
direct interactions between acLaf or y sub-
units with a1, because each of them alters
the properties of the channel when coex-
pressed with al in the absence of the other
auxiliary subunits (although interference of
endogenous a2/, 1, or y cannot be com-
pletely excluded). The effect of the 1 subunit
alone on the biophysical parameters of the
channel is usually negligible, and its direct
contact with a1 is less certain. The combina-
tion of aLJ and 1 subunits is synergistic for
both expression of the channel and channel
properties, conferring activation at more neg-
ative voltages, steep voltage dependence of
inactivation, and less enhancement by Bay K
(at 0 mV). This suggests a strong interaction
between ab8 and P (directly or via al).
Our data and that of others (27) show
that the al subunit is central in determining
the kinetics and the voltage dependence of
activation. This is supported by theoretical
considerations (4). However, other subunits
have modulatory effects: aJb (independent
of the presence of 13 or y) fine tunes the
activation kinetics of the cardiac channel ex-
pressed in the oocyte; as28 combined with 1
increase the voltage sensitivity of activation.
The auxiliary subunits are crucial in deter-
mining both the kinetics and voltage-depen-
dence of the inactivation process; this result
is in contrast to the fact that the inactivation
properties of the voltage-dependent Na'
and K' channels are determined mainly by
their pore-forming subunits (28). Addition
ofaJ/, aJ2/ + 1, or y to a1 sharply increases
the voltage sensitivity of the inactivation pro-
cess; aJ8+P and y but not 13 also strongly
accelerate the current decay. The effect of the
y subunit is especially significant. Once pre-
sent, y dominates the inactivation process,
making it faster and more sensitive to voltage.
This appears to be a voltage- rather than a
REPORTS 1555
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Table 1. The characteristics of IBa directed by different subunit cRNA
combinations. The current amplitudes were measured at 0 mV in a
solution containing 40 mM BaCI2. The entries are mean - SEM; numbers
of oocytes and frogs (n, N) are indicated in the parentheses. Cd2+-
subtraction procedure was used in most cases to obtain net IBa; in some
cases, only leak subtraction was performed (5). Column 2 summarizes
experiments in which 3.3 to 5 ng cRNA (of each subunit) was injected into
the oocyte. Column 3 relates only to cells with IBa over - 10 nA in which
the effect of (-) Bay K 8644 was tested. The increase in IB. caused by Bay
K was calculated in each cell as [(amplitude in Bay K, % of control) -
100%], where "control" denotes IBa before application of Bay K. In
columns 4 to 6, the oocytes were injected with between 0.6 and 25 ng of
cRNA (of each subunit) per oocyte; only cells in which net IBa was
obtained by the Cd2+-subtraction procedure are summarized. In column
5, only cells in which IBa did not exceed -850 nA were taken into account.
NT, not tested.
1 2 3 4 5 6
Subunit Amphtude (nA) Increase in IBa by 90% up deC770 (%) Peak W (mV)
combination Bay K (%) (msec)
a1 alone -5 ± 1 (21, 4) 583 ± 126 (5, 3) 56 ± 9 (8, 2) 4 ± 3 (5, 1) NT*
a1 +aJb -179 ± 22 (49,10) 720 ± 85 (27, 9) 20 ± 1 (26, 5) 20 ± 3 (19, 4) 21 ± 1 (11, 5)
a, + -92 ± 17 (19, 4) 339 ± 113 (17, 5) 44 ± 3 (17, 4) 11 ± 3 (8, 2) 24 ± 2 (8, 2)
a1 +
-Y -123 ± 57 (23, 4)t 348 ± 62 (6, 3) 34 ± 3 (6, 2) 44 ± 3 (4,1) 33, 35 (2, 1)
a, + aA + P -1625 ± 190 (48, 8) 169 ± 34 (14, 4) 19 ± 1 (61, 7) 43 ± 3 (21, 5) 9 ± 2 (13, 3)
a, + aJb + - -912 ± 254 (26, 5)t 402 ± 122 (6, 2) 20 ± 1 (19, 5) 45 ± 4 (6, 3) 23 + 6 (4, 3)
a1 + P3 + -Y -87 ± 13 (14, 3)t 587 ± 127 (9, 2) 39 ± 3 (11, 3) 39 ± 7 (10, 3) 28 ± 2 (5, 1)
a, + aAb + -1076 ± 362 (19, 5)t 425 ± 154 (3, 1) 20 ± 1 (18, 5) 54 ± 4 (10, 4) 19 ± 1 (11, 4)
1 + Y
aJ +13 -46 ± 7 (32, 4) 19 ± 14 (17, 3) 10 ± 1 (18, 3) 63 ± 5 (6, 1) 15 ± 1 (7, 2)
aJ + 13 + y -20 ± 4 (26, 4) 3 ± 4 (9, 2) 10 1 (8, 2) NT NT
aA + -Y -10 ± 3 (8, 1) NT NT NT NT
Uninjected -4 ± 2 (29, 8) NT NT NT NT*
*Peak I-V in oocytes injected with cardiac a, cRNA alone is about 25 mV (6), and of IBa in native oocytes is about 15 mV (17). tMean IBa in pairs of groups differing by
the presence of y were compared. IBa in the a, + aJ28 + y group showed strong frog-to-frog variability and was normalized with respect to IBaa the al + a/b group in oocytes
of the same frogs; this procedure gave ratios between 1 and 5.7 in different experiments (mean 2.0 + 0.7, not significantly different from 1; P > 0.2). a, + y group displayed
IBa between 0 and -20 nA in three experiments and between -200 and -966 nA in a fourth experiment.
Table 2. Parameters of the voltage dependence of steady-state inactivation of IBa directed by
different subunit cRNA combinations. The entries in columns 2, 3, 5, and 6 are mean ± SEM,
except when only one or two cells have been examined, in which cases the values from each cell are
presented. The entries in columns 4 and 7 are the number of oocytes (n) and frogs (N).
1 2 3 4 5 6 7
In 40 mM Ba2+ In 2 mM Ba2+
Group
V112 (mV) Ki (mV) n, N V112 (mV) Ki (mV) n, N
aL alonet 10.4 ± 2.2 24.3 ± 2.8 6, 4
a1 alone 11.1 17.9 1
a1 + a2A -10.2 ± 1.1 14.5 ± 0.7 6, 3
a, + P 2.4 ± 3.6 17.3 ± 2.8 7, 3
aL + y -45; -45.3 18.5; 20.6 2, 1
a1 + -yt -52; -49.8 20; 19.1 2, 1
a1 + a/b+ A* -11.4 ± 1.2 8.5 ± 0.7 8,4 -25.0 ± 0.9 11.3 - 0.4 6, 3
a1 + aJA + Y -41.3 ± 1.9 15.1 ± 0.6 12, 4 -65.4; -68.9 11.1; 7.6 2, 1
al + p + y* -31.4 ± 1.2 14.7 ± 0.6 5, 1
a1 + aJA + -38.5 ± 2.3 13.4 ± 0.8 5, 4 -61.8; -62 11.8; 11.7 2, 2
13+ Y
a218 + P -37.3 ± 4.2 14.7 ± 1.0 6, 2
ax/ + 1 + -y -32.2; -44 17.2; 13.9 2, 1
*The results obtained in solutions with 40 mM BaCI2 and 40 mM barium methanesulfonate were pooled, since no
significant differences in inactivation parameters were detected in these two solutions. In other groups, all results were
obtained in 40 mM BaCI2 solution (16). tIn the presence of 0.5 AM Bay K.
current-dependent phenomenon, since in the
presence of y IBa is inactivated at voltages that
do not cause any current flow through the
channel (Figs. 3 and 4).
Some of the modulatory effects of the
auxiliary subunits may be due to inappropri-
ate interactions between SM and cardiac
channel subunits. Nevertheless, the channel
formed by a1 + ax/b + 13 most closely
resembles the cardiac Ca2+ L channels: slow
but obvious inactivation with Ba2' as the
charge carrier, little inactivation at mem-
brane voltages more negative than -40 mV,
1556
fast activation, Ki of 8 to 9 mV (29). The
channel composed of all four subunits (a1 +
a2/8 + 1 + y) differs from a1 + a2/s + 1
mostly in voltage dependence of inactiva-
tion, resembling the L channels in mamma-
lian SM myocytes and in smooth muscle
cells (30). This is consistent with the pres-
ence ofRNA homologous to that ofthe SM
y subunit in skeletal and smooth muscle but
not in the heart (12, 13). Thus, subunit
composition ofthe Ca2+ channel may deter-
mine some of the tissue-specific differences
between Ca21 channels.
REFERENCES AND NOTES
1. W. A. Catterall, Science 242, 50 (1988); P. Camp-
bell, A. T. Leung, A. H. Sharp, Trends Neurosci. 11,
425 (1988).
2. H. Glossmann and J. Striessnig, Rev. Physiol. Bio-
chem. Pharmacol. 114, 1 (1990); F. Hofmann, V.
Flockerzi, W. Nastainszyk, P. Ruth, T. Schneider,
Curr. Top. Cell. Regul. 31, 223 (1990).
3. T. Tanabe et al., Nature 328, 313 (1987).
4. H. R. Guy and F. Conti, Trends Neurosci. 13, 201
(1990).
5. I. Lotan, P. Goelet, A. Gigi, N. Dascal, Science 243,
666 (1989).
6. A. Mikami et a!., Nature 340, 230 (1989).
7. M. Biel et a!., FEBS Lea. 269, 409 (1990).
8. M. Mori et a!., Nature 350, 398 (1991).
9. K. S. De Jongh, C. Warner, W. A. Catterall, J. Biol.
Chem. 265, 14738 (1990).
10. S. B. Ellis et a!., Science 241, 1661 (1988).
11. P. Ruth et a!., ibid. 245, 1115 (1989).
12. S. D. Jay et a!., ibid. 248, 490 (1990).
13. E. Bosse et al., FEBS Lett. 267, 153 (1990).
14. M. Biel, V. Flockerzi, H. Hoffinann, unpublished
observations.
15. F. C. Chang and M. M. Hosey, J. Biol. Chem. 263,
18929 (1988); M. E. Morton and S. C. Froehner,
Neuron 2, 1499 (1989).
16. The cardiac al cDNA was cloned (M. Biel et a!.,
Eur. J. Biochem., in press) by using the nudeotide
sequence (6), the sequence was deposited in Gen-
Bank (X15539), and the recombinant plasmid
pCaH carrying the protein coding sequence was
constructed. The 3.3-kb Eco RI fragment from
pCaCA1 (6) containing the protein coding region of
the SM aA/b subunit was ligated with the Eco RI
fragment from pSP65 [containing the 0.26-kb BgI
II-Bam HI fragment carrying a poly(dA) poly(dT)
tract from pSPCA1 (6) at the Bam HI site], yielding
pCA2. The recombinant plasmids pCaBl and
pCaGl carrying the protein coding sequences of the
SM 1 (11) and y (13) subunit cDNA, respectively,
were as in (8). mRNA (cRNA) ofthe cardiac al and
skeletal muscle ax28, 13, and - subunits were synthe-
sized in vitro with Asp718-cleaved pCaH, Sal
I-cleaved pCaA2, Sal I-cleaved pCaBI, and Bam
HI-cleaved pCaGI, respectively, as templates. Tran-
scription was primed with the cap dinucleotide
m7G(5')ppp(5')G (1 mM). In each experiment, 20
to 30 defolliculated oocytes were injected with
SCIENCE, VOL. 253
 
o
n
 A
pr
il 3
0,
 2
00
8 
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
cRNAs at 1: 1: 1: 1 stoichiometry. After 3 or 4 days
of incubation at 22TC (5), the oocytes were injected
with 200 pmol of EGTA (K' salt, pH 7) 1 day
before testing the currents. IBa was measured at
22TC in 40 mM Ba2+, 2 mM K+, 60 mM Na+, and
5 mM Hepes (pH 7.4 to 7.5); the anion was either
Cl- or methanesulfonate. A low Ba2+ solution
containing 2 mM BaCl2, 96 mM NaCl, 2 mM KCl,
5 mM Hepes (pH 7.5) was used in some cases. The
two-electrode voltage damp, data acquisition, and
subtraction procedures were as in (5). The precision
of the rise time measurement was within +3 ms [N.
Dascal and I. Lotan, Neuron 6, 165 (1991)]. The
precision ofcurrent measurement was usually within
±3 nA. The holding potential was -80 mV. The
Ba2+-dependent decrease in IBa in cells with large
currents upon frequent repetitive depolarizations
was avoided by using interpulse intervals that al-
lowed a full recovery ofIBa (5 to 40 s, depending on
current amplitude).
17. N. Dascal, T. P. Snutch, H. Lubbert, N. Davidson,
H. A. Lester, Science 231, 1147 (1986); J. A.
Umbach and C. B. Gundersen, Proc. Natt. Acad. Sci.
U.SA. 84, 5464 (1987); P. Lory, F. A. Rassen-
dren, S. Richard, F. Tiaho, J. Nargeot, J. Physiol.
(London) 429, 95 (1990).
18. N. Dascal, I. Lotan, A. Gigi, E. Karni, manuscript in
preparation.
19. R. G. Audet, J. Goodchild, J. D. Richter, Dev. Biol.
121, 58 (1987).
20. P. L. Donaldson and K. G. Beam, J. Gen. Physiol.
82, 449 (1983); J. A. Sanchez and E. Stefani, J.
Physiol. (London) 337, 1 (1983); K. B. Walsh, T. B.
Begenesih, R. S. Kass, J. Gen. Physiol. 93, 841
(1989).
21. The multiexponential character ofIBa decay prevent-
ed a more rigorous analysis.
22. R. S. Kass and M. C. Sanguinetti, J. Gen. Physiol.
84, 705 (1984); K. S. Lee, E. Marban, R. W. Tsien,
J. Physiol. (London) 364, 395 (1985); D. L. Camp-
bell, W. R. Giles, J. R. Hume, E. F. Shibata, ibid.
403, 287 (1988).
23. In this solution, Cl- leaves the cell at all potentials,
producing an inward current, which may introduce
another artifact when IBa is large-an apparent
slowing of the decay.
24. A. L. Hodgkin and A. F. Huzley, J. Physiol.
(London) 117, 500 (1952). Only cells with IBa
smaller than -1500 nA were tested. The inactiva-
tion curves were fitted to the equation IBJImax =
1/{1 + exp[(V - V112)/K;]}, where I.., wasthe current obtained by the step from - 100 to 20
mV. For details on fitting procedure, see (31).
25. Steady-state inactivation was studied in the presence
of Bay K in most cells of the a, group and in some
cells of the ao + y group to assure reliable measure-
ment of currents. Bay K causes a slight (about 5
mV) shift of the inactivation curve to negative
potentials (29).
26. B. Hille, Ionic Channels ofExcitable Membranes (Sin-
auer, Sunderland, MA, 1984); R. S. Kass and D. S.
Krafte, J. Gen. Physiol. 89, 629 (1987).
27. T. Tanabe, K. G. Beam, B. A. Adams, T. Niidome,
S. Numa, Nature 346, 567 (1990); E. Perez-Reyes
et al., ibid. 340, 233 (1989); B. A. A. Adams, T.
Tanabe, A. Mikami, S. Numa, K. G. Beam, ibid.
346, 569 (1990).
28. W. Stuhmer et al., Nature 339, 597 (1989); D. S.
Krafte et al., J. Gen. Physiol. 96, 689 (1990); T.
Hoshi, W. N. Zagotta, R. W. Aldrich, Science 250,
533 (1990).
29. A. M. Brown, D. L. Kunze, A. Yatani, J. Physiol.
(London) 379,495 (1986); S. Hering, T. Kleppisch,
E. N. Timin, R. Bodewei, Pfluegm Arch. 414,690(1989).
30. C. Cognard, G. Romey, J.-P. Galizzi, M. Fosset, M.
Lazdunski, Proc. Natl. Acad. Sci. U. S.A. 83, 1518
(1986); P. I. Aaronson, T. B. Bolton, R. J. Lang, I.
MacKenzie, J. Physiol. (London) 405, 57 (1988).
31. We thank T. Tanabe and S. Numa for providing
pSPCA1; D. Gordon, R. Korenstein, and S. Cohen
for critical reading of the manuscript; Bay K was a
gift from Bayer AG. Supported in part by grants
from the Schlezak Fund to N.D. and I.L., Deutsche
Forschungsgemeinschaft, Thissen and Fond der
Chemischen Industrie to V.F. and F.H.
18 April 1991; accepted 31 July 1991
Resistance to ddl and Sensitivity to AZT Induced by
a Mutation in HIV-1 Reverse Transcriptase
M. H. ST. CLAIR,* J. L. MART1I, G. TUDOR-WILLIAMS, M. C. BACH,
C. L. VAVRO, D. M. KING, P. KELLAM, S. D. KEMp, B. A. LARDER
Serial human immunodeficiency virus type-1 (HIV-1) isolates were obtained from five
individuals with acquired immunodeficiency syndrome (AIDS) who changed therapy
to 2',3'-dideoxyinosine (ddI) after at least 12 months of treatment with 3'-azido-3'-
deoxythymidine (zidovudine, AZT). The in vitro sensitivity to ddI decreased during
the 12 months following ddI initiation, whereas AZT sensitivity increased. Analysis of
the reverse transcriptase coding region revealed a mutation associated with reduced
sensitivity to ddI. When this mutation was present in the same genome as a mutation
known to confer AZT resistance, the isolates showed increased sensitivity to AZT.
Analysis ofHIV-1 variants confirmed that the ddI resistance mutation alone conferred
ddl and 2',3'-dideoxycytidine resistance, and suppressed the effect of the AZT
resistance mutation. The use of combination therapy for HIV-1 disease may prevent
drug-resistant isolates from emerging.
E XPERIENCE IN TREATING HIV- 1-IN-
fected individuals has raised concerns
regarding therapy with antiviral
agents. Several studies have drawn attention
to the emergence of resistant HIV strains in
individuals on long-term therapy with AZT
alone (1, 2). The clinical implications of
reduced susceptibility to AZT are not yet
fully understood; the appearance of AZT-
resistant variants is not associated with a
sudden clinical deterioration (1). Some in-
dividuals who have become intolerant to
AZT or appear to be deteriorating clinically
have changed therapy to other potentially
effective drugs, including ddl (3), after dis-
continuing AZT. To discover if HIV iso-
lates from such individuals develop resis-
tance to ddI and if ddl therapy has any
influence on AZT sensitivity we studied
sequential isolates from five individuals who
had received AZT for at least 12 months and
were switched to ddI after they appeared to
deteriorate clinically (4).
HIV was recovered from peripheral blood
mononuclear cells (PBMCs) by cocultiva-
tion with donor HIV- PBMCs (5), and
drug sensitivity was assessed with a PBMC-
based assay (6). All isolates recovered at the
time therapy was switched had reduced
sensitivity to AZT. AZT therapy was dis-
continued and ddli started (with informed
consent). Within 6 to 12 months of dis-
continuing AZT therapy, the isolates were
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Division of Virology, Burroughs Wellcome Co., Re-
search Triangle Park, NC 27709.
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Wellcome Co., Research Triangle Park, NC 27709, and
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M. C. Bach, Maine Medical Center, Portland, ME
04102.
P. Kellam, S. D. Kemp, B. A. Larder, Division of
Molecular Sciences, Wellcome Research Laboratories,
Beckenham, Kent BR3 3BS, United Kingdom.
*To whom correspondence should be addressed.
substantially more sensitive to AZT. Dur-
ing the same time period, a 6- to 26-fold
decrease in ddl sensitivity was observed. A
representative sensitivity profile for isolates
from one individual is illustrated in Fig. 1.
After 12 months of ddI therapy, the AZT
IC50 (50% inhibitory concentration) had
dropped from a high of greater than 10
liM to 0.73 pM AZT, whereas the ddl
JC50's for the same isolates increased from
0.3 ILM to 9 FLM.
Studies have demonstrated that multiple
common mutations in the HIV-1 reverse
transcriptase (RT) coding region confer re-
sistance to AZT (7). Variants with reduced
AZT sensitivity were found to contain one
or more amino acid changes at codons 67,
70, 215, or 219. To identify mutations in
the RT coding region associated with the
observed resistance to ddI, we determined
the complete nucleotide sequence of the
10.
8
6.
2-
0
-2 6 2 4 6 8 10 12
Months after therapy change
Fig. 1. In vitro sensitivities (IC50's) to ddI (0)
and AZT (-) of sequential HIV isolates from an
individual with AIDS. This graph is illustrative of
changes seen in five individuals (4). At time 0
AZT therapy was discontinued, and ddI therapy
(4 mg per kilogram of body mass every 12 hours)
was initiated. Blood samples were obtained as
shown before, at the time of, and at various times
after the change in antiviral therapy. Virus was
isolated and analyzed for sensitivity to AZT and
ddI as described (5, 6).
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